The Multiple Myeloma Research Foundation (MMRF) is a 501(c)(3) non-profit organization established in 1998. The group’s mission is to find a cure for multiple myeloma by pursuing innovation that accelerates the development of next-generation treatments to extend the lives of patients.
The MMRF is focused on using precision medicine to help patients get the right treatment based on their specific molecular information. The MMRF gathers, generates and analyzes vital information about multiple myeloma, patients, and treatments, shares the data with researchers and institutions, and evaluates new treatments through a collaborative research consortium. These efforts are helping to accelerate discovery and produce better, more targeted treatments for people living with multiple myeloma.
Program Description
The Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile study (CoMMpassSM, NCT01454297) is the MMRF’s landmark personalized medicine initiative. CoMMpass is a longitudinal observation study of around 1000 newly diagnosed myeloma patients receiving various standard approved treatments.
The MMRF’s vision is to track the treatment and results for each CoMMpass patient so that someday the information can be used to guide decisions for newly diagnosed patients. CoMMpass checked on patients every 6 months for 8 years, collecting tissue samples, genetic information, quality of life and various disease and clinical outcomes. The study has produced one of the largest genomic and clinical datasets of a single disease.
Data Overview
Data Access
The MMRF genomic data can be found on the GDC Data Portal. To request access to protected MMRF data, please apply to dbGaP for access to the MMRF Study (study accession phs000748).
Data from a total of 995 cancer patients with multiple myeloma are available. Genomic data includes DNA sequences from whole genome sequencing (WGS) and whole exome sequencing (WXS), and RNA sequences. Clinical data includes demographics, diagnoses, family histories, molecular tests, and treatments.
The data includes detailed longitudinal information generated as patients were tracked over the course of their disease. 111 of the cases have sequencing data from two or more timepoints. On average, there are 9 timepoints per case and 15 clinical lab values per timepoint.
Cancer Types
- Multiple Myeloma
Data Types
| Data Type | Data Format | Data Access Level |
|---|---|---|
| Clinical and Biospecimen | TSV, JSON | Open |
| WGS Aligned Reads | BAM | Controlled |
| WXS Aligned Reads | BAM | Controlled |
| WXS Raw Simple Somatic Mutations | VCF | Controlled |
| WXS Annotated Somatic Mutations | VCF | Controlled |
| WXS Aggregated Somatic Mutations | MAF | Controlled |
| WXS Masked Somatic Mutations | MAF | Open |
| RNA-Seq Aligned Reads | BAM | Controlled |
| RNA-Seq Gene Expression Quantification | TXT | Open |
| RNA-Seq Splice Junction Quantification | TXT | Controlled |